JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

United Therapeutics Corp

Gesloten

SectorGezondheidszorg

300.38 -0.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

299.56

Max

305.38

Belangrijke statistieken

By Trading Economics

Inkomsten

-13M

310M

Verkoop

4.2M

799M

K/W

Sectorgemiddelde

11.414

34.393

EPS

6.63

Winstmarge

38.755

Werknemers

1,305

EBITDA

-18M

365M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+25.73% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-213M

13B

Vorige openingsprijs

300.92

Vorige sluitingsprijs

300.38

Nieuwssentiment

By Acuity

97%

3%

363 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

United Therapeutics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2024, 15:14 UTC

Belangrijke Marktbewegers

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Peer Vergelijking

Prijswijziging

United Therapeutics Corp Prognose

Koersdoel

By TipRanks

25.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 379.08 USD  25.73%

Hoogste 510 USD

Laagste 295 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor United Therapeutics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technische score

By Trading Central

292.345 / 309.245Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

363 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.